Adicet Bio (ACET) vs LeonaBio (LONA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LeonaBio (LONA) has outperformed Adicet Bio (ACET) over the past year, gaining 51.0% versus a loss of 61.4%. Over five years, LONA leads with a -93.9% price change compared with -95.5% for ACET. LeonaBio is the larger company by market cap ($54.2 million vs $53.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACET | LONA |
|---|---|---|
| Share price | $5.74 | $5.75 |
| Market cap | $53.73M | $54.17M |
| 1-day change | -7.12% | -1.37% |
| YTD return | -31.83% | -22.99% |
| 1-year return | -61.38% | +51.04% |
| 5-year return | -95.54% | -93.90% |
| EPS (TTM) | $-10.42 | $-23.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.44 | $14.21 |
| 52-week low | $5.55 | $2.21 |
| Distance from 52-week high | -67.09% | -59.54% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +506.79% | +201.39% |
| Average volume | 172.38K | 185.45K |
| Shares outstanding | 9.36M | 9.42M |
| Employees | 102 | 19 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LONA has outperformed ACET by 112.4 percentage points over the past year.
About Adicet Bio
ACET stock →Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.
Healthcare · Biotechnology · 102 employees
About LeonaBio
LONA stock →LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective.
Healthcare · Biotechnology · 19 employees
ACET vs LONA FAQ
Which is bigger, Adicet Bio or LeonaBio?
LeonaBio (LONA) is larger, with a market capitalization of $54.17M compared with $53.73M for Adicet Bio (ACET).
Which stock has performed better over the past year, ACET or LONA?
LONA returned +51.04% over the past 12 months, compared with -61.38% for ACET (price return, excluding dividends). Past performance does not predict future results.
Are Adicet Bio and LeonaBio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.